Loading...
NPI 1447437355 · Aliso Viejo, CA · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Neogenomics Laboratories Inc is a clinical medical laboratory provider located in Aliso Viejo, California. This profile covers 58 Medicare and 63 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Neogenomics Laboratories Inc |
| Address | 31 Columbia |
| City | Aliso Viejo |
| State | CA |
| ZIP | 92656 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | January 23, 2008 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $32.6M |
| Medicaid | $21.5M |
NEOGENOMICS LABORATORIES INC reports materially larger Medicare receipts than Medicaid on a lifetime basis, with Total Medicare revenue of $32.6M versus Total Medicaid revenue of $21.5M. Both payers are meaningful to the business, but Medicare is the single largest payer by dollars, indicating the lab’s commercial scale skews toward Medicare beneficiaries and fee schedules.
Revenue concentration is high on both payers. For Medicare the precomputed top-3 codes account for 63.7% of Medicare revenue, led by 81479 which alone represents 49.6% of the provider’s Medicare revenue; for Medicaid the precomputed top-3 codes account for 49.1% of Medicaid revenue, with 88185, 81455 and 88377 together driving that share. These concentrations imply the business’s topline is sensitive to reimbursement and utilization changes for a handful of test families.
The code mix indicates a specialized oncology and complex pathology operation: high-revenue molecular and genomic panels (81479, 81450, 81455, 81449, and PLA 0388U) sit alongside large volumes of in situ hybridization and immunohistochemistry work (88374, 88377, 88341, 88360, 88342). Substantial flow cytometry and cytogenetics activity (88185, 88184, 88189, 88237, 88264, 88291) further positions the lab as a full-service cancer diagnostic reference lab supporting both solid tumor and hematolymphoid testing.
National competitive standing on Medicare is strong in many specialized test lines: the provider ranks at or near the top nationally for multiple codes (for example 88377 ranks #1 of 616, 88374 #2 of 378, 88237 #1 of 107, 81263 #1 of 48), and numerous codes are labeled “extreme outlier, far above typical national volume.” This pattern shows NEOGENOMICS is a major national supplier for select pathology, cytogenetic, and molecular assays rather than a modest local lab for those services.
State-level competitive standing on Medicaid is similarly dominant for key assays: the provider ranks #1 in-state for multiple high-revenue Medicaid codes including 81455, 88377, 88374, 88341, 88237 and others, and 88185 is a very large in-state performer (27.3K claims, $5.8M revenue) ranked #2 of 37. These in-state rank positions and the frequent “extreme outlier” and “notably above typical” labels indicate strong market share across California for oncology and hematology testing.
Multiple individual code volumes are statistical outliers and concentrated contributors to revenue. Examples include Medicare 88185 (81.2K claims, $1.8M revenue; labeled “extreme outlier”), Medicare 88374 (22.6K claims, $2.4M revenue; labeled “extreme outlier”), and Medicaid 88377 (23.5K claims, $2.1M revenue; ranked #1 in-state and labeled “notably above typical”). The frequency of “extreme outlier” and “notably above typical” labels across many codes suggests a persistent pattern of very high throughput for specialized diagnostic testing.
Dependence on uncoded or broadly used molecular pathology reporting is a notable operational characteristic: 81479 is the single largest Medicare revenue driver at $15.4M (49.6% of Medicare revenue) yet is described in the file as having “typical, unremarkable volume” on national rank #7 of 80. This combination — large dollar concentration in 81479 alongside other highly ranked specific assays — suggests revenue sensitivity to how complex molecular testing is packaged and coded, and it may complicate benchmarking against peers that use more code-specific reporting.
The provider has an established operating history with NPI enumeration on 2008-01-23 (~18 years ago), and that tenure aligns with the breadth and scale of testing observed across both payers. Long-term enumeration plus dominant rank positions for many specialized codes supports the conclusion that NEOGENOMICS operates as a mature reference lab with deep penetration in molecular oncology, cytogenetics, and pathology services.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
58 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 81479 | Use 81479 to report a molecular pathology procedure that does not have a specific code. | 9,600 | $1,610 | $15.4M |
| 88374 | The lab analyst applies a single multiplex in situ hybridization probe stain on a slide or slides prepared from a single patient specimen, such as tumor tissue. The lab analyst processes the slides… | 22,590 | $110 | $2.4M |
| 81450 | The lab analyst performs a genomic sequence analysis panel to evaluate the patient specimen, such as blood or bone marrow, for DNA and possibly RNA alterations in five to 50 genes known to impact… | 2,670 | $740 | $2M |
| 88377 | The lab analyst applies a single multiplex in situ hybridization probe stain on a slide or slides prepared from a single patient specimen, such as tumor tissue. Then a qualified provider, typically a… | 10,450 | $180 | $1.9M |
| 88185 | The lab analyst performs the technical component of a flow cytometry procedure using cell surface, cytoplasmic, or nuclear markers to characterize cells and aid clinicians in diagnosing patients with… | 81,150 | $20 | $1.8M |
| 88341 | The lab analyst applies an additional single antibody stain on a slide or slides prepared from the same patient specimen as the initial antibody stain, such as tumor tissue. Then a qualified… | 31,380 | $40 | $1.3M |
| 88360 | The lab analyst applies a single antibody stain on a slide or slides prepared from a single patient specimen, such as tumor tissue. Then a qualified provider, typically a pathologist, evaluates the… | 12,010 | $60 | $756.8K |
| 88342 | The lab analyst applies an initial single antibody stain on a slide or slides prepared from a single patient specimen, such as tumor tissue. Then a qualified provider, typically a pathologist,… | 11,750 | $60 | $646.3K |
| 88237 | The lab analyst performs a procedure to grow a culture of cells from bone marrow or blood in a neoplastic disorder. | 4,310 | $140 | $607.6K |
| 88361 | The lab analyst applies a single antibody stain on a slide or slides prepared from a single patient specimen, such as tumor tissue. The lab analyst processes the slides using computer assisted… | 7,890 | $60 | $488.9K |
Showing 1–10 of 58
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 58 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
58 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| 81479 | 5 | 20 | 650 | $2,290 | $16.6M |
| 81450 | 1 | 10 | 60 | $740 | $679.4K |
| 0388U | 1 | 10 | 130 | $3,430 | $459.6K |
| 81449 | 1 | 10 | 280 | $590 | $161.1K |
| 81339 | 1 | 10 | 830 | $180 | $150.3K |
| 81305 | 1 | 10 | 850 | $170 | $146K |
| 88185 | 2 | 40 | 1,560 | $20 | $139.2K |
| 81288 | 1 | 10 | 660 | $190 | $124.8K |
| 81206 | 1 | 10 | 200 | $160 | $123.5K |
| 88120 | 4 | 20 | 120 | $400 | $122.8K |
Showing 1–10 of 58
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
63 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 88185 | The lab analyst performs the technical component of a flow cytometry procedure using cell surface, cytoplasmic, or nuclear markers to characterize cells and aid clinicians in diagnosing patients with… | 27,340 | $210 | $5.8M |
| 81455 | The lab analyst performs a genomic sequence analysis panel to evaluate the patient specimen, such as tumor tissue or bone marrow, for DNA and possibly RNA alterations in 51 or more genes known to… | 3,850 | $560 | $2.1M |
| 88377 | The lab analyst applies a single multiplex in situ hybridization probe stain on a slide or slides prepared from a single patient specimen, such as tumor tissue. Then a qualified provider, typically a… | 23,510 | $90 | $2.1M |
| 88374 | The lab analyst applies a single multiplex in situ hybridization probe stain on a slide or slides prepared from a single patient specimen, such as tumor tissue. The lab analyst processes the slides… | 22,620 | $90 | $2.1M |
| 88341 | The lab analyst applies an additional single antibody stain on a slide or slides prepared from the same patient specimen as the initial antibody stain, such as tumor tissue. Then a qualified… | 15,990 | $90 | $1.5M |
| 88237 | The lab analyst performs a procedure to grow a culture of cells from bone marrow or blood in a neoplastic disorder. | 14,360 | $60 | $904.5K |
| 88361 | The lab analyst applies a single antibody stain on a slide or slides prepared from a single patient specimen, such as tumor tissue. The lab analyst processes the slides using computer assisted… | 11,170 | $70 | $793.2K |
| 88184 | The lab analyst performs the technical component of a flow cytometry procedure using a cell surface, cytoplasmic, or nuclear marker to characterize cells and aid clinicians in diagnosing patients… | 22,760 | $30 | $751K |
| 88360 | The lab analyst applies a single antibody stain on a slide or slides prepared from a single patient specimen, such as tumor tissue. Then a qualified provider, typically a pathologist, evaluates the… | 28,610 | $30 | $715.3K |
| 88342 | The lab analyst applies an initial single antibody stain on a slide or slides prepared from a single patient specimen, such as tumor tissue. Then a qualified provider, typically a pathologist,… | 31,870 | $20 | $541.8K |
Showing 1–10 of 63
How this provider's Medicaid billing volume and revenue compare to other California providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. California median
63 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 81479 | Use 81479 to report a molecular pathology procedure that does not have a specific code. | 11 | 50 | 500 | $160 | $1.1M |
| 81405 | The lab analyst performs the technical lab tests to complete one of the specific genetic analyses listed in this Tier 2, Level 6 molecular pathology code. | 12 | 10 | 470 | $20 | $670.1K |
| 81455 | The lab analyst performs a genomic sequence analysis panel to evaluate the patient specimen, such as tumor tissue or bone marrow, for DNA and possibly RNA alterations in 51 or more genes known to… | 1 | 10 | 80 | $660 | $439.2K |
| 88374 | The lab analyst applies a single multiplex in situ hybridization probe stain on a slide or slides prepared from a single patient specimen, such as tumor tissue. The lab analyst processes the slides… | 1 | 10 | 90 | $90 | $371.2K |
| 88185 | The lab analyst performs the technical component of a flow cytometry procedure using cell surface, cytoplasmic, or nuclear markers to characterize cells and aid clinicians in diagnosing patients with… | 2 | 40 | 220 | $140 | $354.7K |
| 81404 | The lab analyst performs the technical lab tests to complete one of the specific genetic analyses listed in this Tier 2, Level 5 molecular pathology code. | 12 | 10 | 620 | $50 | $304.8K |
| 81406 | The lab analyst performs the technical lab test to complete one of the specific genetic analyses listed in this Tier 2, Level 7 molecular pathology code. | 15 | 20 | 590 | $40 | $274.7K |
| 88377 | The lab analyst applies a single multiplex in situ hybridization probe stain on a slide or slides prepared from a single patient specimen, such as tumor tissue. Then a qualified provider, typically a… | 1 | 10 | 110 | $100 | $252.6K |
| 81445 | The lab analyst performs a genomic sequence analysis panel to evaluate the patient tumor specimen for DNA and possibly RNA alterations in five to 50 genes known to impact solid organ cancers. | 1 | 10 | 2,510 | $90 | $223.5K |
| 88305 | The physician, typically a pathologist, performs a level IV examination of a surgical pathology specimen. The examination includes accessioning the specimen into the lab, which involves formally… | 317 | 830 | 880 | $40 | $195.6K |
Showing 1–10 of 63
Other providers in the same ZIP code as Neogenomics Laboratories Inc, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Ambry Genetics Corporation | CA | Clinical Medical Laboratory | $40.8M | $47.4M |
| Bridge Diagnostics LLC | CA | Clinical Medical Laboratory | $352.5K | $8.5M |
| Kenneth Martinez | CA | Neurology Physician | $1.6M | $7.8K |
| George Shahinian | CA | Pulmonary Disease Physician | $976.4K | $2.2K |
| Ambika Bhushan | CA | Internal Medicine Physician | $207.8K | $0 |
| Parastou Abedi | CA | Ophthalmology Physician | $190.4K | $15K |
| Vangie Tran | CA | Family Nurse Practitioner | $200K | $0 |
| Maria Criselda Leoncio | CA | Physical Therapist | $194.2K | $0 |
| Mindy Bixby | CA | Neurology Physician | $107.9K | $33.2K |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.